Scholarlink

<p>Multidrug-resistant (MDR) <i>Shigella</i> spp. threaten global health, renewing interest in phage therapy. Here, we report the isolation and characterization of a novel lytic phage, SSG23, effective against four major <i>Shigella</i> serovars. Phage SSG23 possesses a prolate head and contractile tail, consistent with the <i>Straboviridae</i> family, and remains stable across a broad pH (4–11) and temperature range (−20 °C to 50 °C). It exhibits a latent period of 37 minutes, a burst size of 195 plaque-forming units per cell, and a 168,820 bp dsDNA genome with 40.8% GC content lacking resistance or toxin genes. SSG23 efficiently degrades biofilms, alone or with antibiotics, and is non-toxic to macrophages in vitro. In <i>S. sonnei</i>-infected BALB/c mice, oral administration reduced bacterial colonization and shedding while improving health without evidence of resistance emergence. Neutralizing antibodies developed in mice, yet the phage maintained its efficacy. These findings support SSG23 as a promising candidate for phage therapy against <i>Shigella</i> infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic potential of Shigella phage SSG23 against Shigella sonnei biofilms and in BALB/c mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Payel Mondal,
  • Sanjib Das,
  • Anaswara Ramesh,
  • Arpita Sarbajna,
  • Soumalya Banerjee,
  • Subhadip Bhaumik,
  • Hemanta Koley

摘要

Multidrug-resistant (MDR) Shigella spp. threaten global health, renewing interest in phage therapy. Here, we report the isolation and characterization of a novel lytic phage, SSG23, effective against four major Shigella serovars. Phage SSG23 possesses a prolate head and contractile tail, consistent with the Straboviridae family, and remains stable across a broad pH (4–11) and temperature range (−20 °C to 50 °C). It exhibits a latent period of 37 minutes, a burst size of 195 plaque-forming units per cell, and a 168,820 bp dsDNA genome with 40.8% GC content lacking resistance or toxin genes. SSG23 efficiently degrades biofilms, alone or with antibiotics, and is non-toxic to macrophages in vitro. In S. sonnei-infected BALB/c mice, oral administration reduced bacterial colonization and shedding while improving health without evidence of resistance emergence. Neutralizing antibodies developed in mice, yet the phage maintained its efficacy. These findings support SSG23 as a promising candidate for phage therapy against Shigella infection.